Quarterly report pursuant to Section 13 or 15(d)

Stockholders??? Equity

v3.21.2
Stockholders’ Equity
6 Months Ended
Jun. 30, 2021
Equity [Abstract]  
Stockholders’ Equity

Note 6 – Stockholders’ Equity

 

Our authorized capital stock consists of 50 million shares of common stock, $0.0005 par value, and one million shares of preferred stock, $0.0005 par value.

 

Preferred Stock

 

The preferred stock authorized under our certificate of incorporation may be issued from time to time in one or more series. As of June 30, 2021 and December 31, 2020, no shares of preferred stock have been issued.

 

Common Stock Dividends

 

On May 13, 2021, the Board declared a special cash dividend of $0.30 per share on the Company’s common stock to holders of record on May 25, 2021, resulting in the payment of $4.5 million to stockholders on June 3, 2021.

 

In Fiscal 2020, no cash dividends were declared.

 

Common Stock

 

Registered Direct Offering

 

On January 5, 2021, we entered into a securities purchase agreement with certain accredited investors and qualified institutional buyers, pursuant to which we issued and sold to the purchasers an aggregate of (i) 550,000 shares of our common stock, and (ii) warrants to purchase up to 275,000 shares of common stock in a registered direct offering.

 

The shares and warrants were sold at a purchase price of $10.00 per share for net proceeds of $5.5 million. Each Warrant has an exercise price equal to $11.00 per share of common stock, will be exercisable at any time and from time to time, subject to certain conditions described in the Warrant, after the date of issuance, and will expire on the date that is three years from the date of issuance. The Shares and the Warrants are immediately separable and were issued separately.

 

Public Offering

 

On January 18, 2021, we entered into an underwriting agreement for the public offering of 3 million shares of common stock, at a price to the public of $12.50 per share. We also issued to the Underwriters warrants to purchase up to an aggregate of 180,000 shares of common stock (6% of the shares of common stock sold in the offering) at an exercise price of $15.625 per share (equal to 125% of the public offering price per share). On January 21, 2021, we completed the offering for net proceeds of $35.1 million, after deducting the underwriting discounts and commissions and estimated offering expenses.

 

 

The 2010 Directors’ Equity Compensation Plan

 

On May 20, 2021, the stockholders of the Company approved the Amended and Restated 2010 Directors’ Equity Compensation Plan (the “Amended 2010 Directors’ Plan”) at the 2021 Annual Meeting of Stockholders of the Company (the “2021 Annual Meeting”). The Amended 2010 Directors’ Plan had been previously approved by the board of directors of the Company on April 7, 2021, subject to stockholder approval at the 2021 Annual Meeting.

 

The Amended 2010 Directors’ Plan provides for an increase in the number of shares reserved for issuance under the plan by 100,000 shares, from 675,000 shares to 775,000 shares.

 

During the three and six months ended June 30, 2021, no shares of common stock and options were granted to our directors under the 2010 Directors’ Plan.

 

During the three and six months ended June 30, 2020, 9,709 and 18,055 shares of common stock, respectively were granted to our directors under the 2010 Directors’ Plan. We recorded $35,000 of director fees during the six months ended June 30, 2020 in connection with these grants, which represented the fair value of the shares calculated based on the average closing price of our shares of common stock for the last five trading days of the quarter in which the Board fee was earned.

 

At June 30, 2021, there were 200,000 options outstanding and there were 228,126 shares of common stock available to be issued pursuant to the terms of the 2010 Directors’ Plan. No stock options were exercised during the six months ended June 30, 2021.

 

The 2010 Equity Compensation Plan

 

On May 20, 2021, the stockholders of the Company approved the Amended and Restated 2010 Equity Compensation Plan (the “Amended 2010 Plan”) at the 2021 Annual Meetings. The Amended 2010 Plan had been previously approved by the board of directors of the Company on April 7, 2021, subject to stockholder approval at the 2021 Annual Meeting.

 

The Amended 2010 Plan provides for an increase in the number of shares reserved for issuance under the plan by 1,000,000 shares, from 3,900,000 shares to 4,900,000 shares.

 

There were 675,000 options granted under the 2010 Plan during the six months ended June 30, 2021 for a total fair value of $1,973,000.

 

As of June 30, 2021, there were 1,890,250 options outstanding and 340,659 options available to be issued pursuant to the terms of the 2010 Plan. We will recognize an aggregate of approximately $1,583,000 of remaining share-based compensation expense related to outstanding stock options over a weighted average period of 3.0 years. No stock options were exercised during the six months ended June 30, 2021.

 

The 2018 Stock Incentive Plan

 

On April 12, 2018, our stockholders approved the 2018 Stock Incentive Plan (the “2018 Stock Plan”). At April 12, 2018, all 2.3 million shares available for issuance under the 2018 Stock Plan have been granted in the form of a stock option with an initial exercise price of $3.00 per share, which are exercisable in 36 monthly installments, to Ted Karkus (the “CEO Option”), our Chief Executive Officer. No stock options have been exercised during the six months ended June 30, 2021 and 2020.

 

The 2018 Plan requires certain proportionate adjustments to be made to stock options granted upon the occurrence of certain events, including a special distribution (whether in the form of cash, shares, other securities, or other property) in order to maintain parity. Accordingly, the Compensation Committee of the board of directors, as required by the terms of the 2018 Stock Plan, adjusted the terms of the CEO Option, such that the exercise price of the CEO Option was reduced from $3.00 per share to $2.00 per share, effective as of September 5, 2018, the date a special $1.00 special cash dividend was paid to the Company’s stockholders. The exercise price of the CEO Option was further reduced from $2.00 to $1.75 per share, effective as of January 24, 2019, the date a $0.25 special cash dividend was paid to the Company’s stockholders. The exercise price of the CEO Option was further reduced from $1.75 to $1.50 per share, effective as of December 12, 2019, the date another $0.25 special cash dividend was paid to Company’s stockholders. The exercise price of the CEO Option was further reduced from $1.50 to $1.20 per share, effective as of June 3, 2021, the date another $0.30 special cash dividend was paid to Company’s stockholders.

 

 

The following table summarizes stock options activity during the six months ended June 30, 2021 for the Amended 2010 Plan, the Amended 2010 Directors’ Plan and the 2018 Stock Plan (in thousands, except per share data):

    Number of Shares     Weighted Average Exercise Price     Weighted Average Remaining Contractual Life
(in years)
    Total Intrinsic Value  
Outstanding as of January 1, 2021     3,795     $ 2.21       3.4     $ 26,441  
Granted     675       9.13       5.1       -  
Forfeited     (92 )     5.31       -       -  
Outstanding as of June 30, 2021     4,378     $ 3.06       3.2     $ 16,182  
Options vested and exercisable     3,573     $ 2.22       2.7     $ 15,183  

 

The following table summarizes weighted average assumptions used in determining the fair value of the options at the date of grant during the six months ended June 30, 2021:

    For the six months ended  
    June 30, 2021  
Exercise price   $ 9.13  
Expected term (years)     3.5  
Expected stock price volatility     83 %
Risk-free rate of interest     0.6 %
Expected dividend yield (per share)     0 %

 

During the six months ended June 30, 2021, we issued warrants to purchase 275,000 shares of common stock in a registered direct offering and warrants to purchase 180,000 shares of common stock to the underwriters in a public offering. The following table summarizes warrant activities during the six months ended June 30, 2021 (in thousands, except per share data).

    Number of Shares     Weighted Average Exercise Price     Weighted Average Remaining Contractual Life
(in years)
 
Outstanding as of January 1, 2021     450     $ 3.22       2.7  
Warrants granted     455       12.83       3.0  
Outstanding as of June 30, 2021     905     $ 8.05       2.4  
Warrants vested and exercisable     815     $ 8.61       2.4  

 

The following table summarizes weighted average assumptions used in determining the fair value of the warrants at the date of grant during the six months ended June 30, 2021:

    For the six months ended  
    June 30, 2021  
Exercise price   $ 12.83  
Expected term (years)     3.0  
Expected stock price volatility     81 %
Risk-free rate of interest     0.2 %
Expected dividend yield (per share)     0 %

 

As of June 30, 2021, there were 905,000 warrants outstanding and we recognized $105,000 and $193,000 of share-based compensation expense during the three and six months ended June 30, 2021. We had no compensation expense during the six months ended June 30, 2020.